Spectranetics (SPNC) Receiving Somewhat Favorable News Coverage, Analysis Finds
News coverage about Spectranetics (NASDAQ:SPNC) has trended somewhat positive on Thursday, Accern Sentiment reports. The research group ranks the sentiment of press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Spectranetics earned a daily sentiment score of 0.03 on Accern’s scale. Accern also gave media headlines about the medical equipment provider an impact score of 45.4691319816145 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Shares of Spectranetics (SPNC) opened at $38.45 on Thursday. The firm has a market capitalization of $1,680.00, a PE ratio of -24.18 and a beta of 1.54. The company has a debt-to-equity ratio of 7.61, a quick ratio of 1.43 and a current ratio of 1.92. Spectranetics has a twelve month low of $19.80 and a twelve month high of $38.55.
TRADEMARK VIOLATION WARNING: This report was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this report on another domain, it was illegally stolen and republished in violation of U.S. and international trademark & copyright legislation. The original version of this report can be accessed at https://www.watchlistnews.com/spectranetics-spnc-receiving-somewhat-favorable-news-coverage-analysis-finds/1793866.html.
Spectranetics Company Profile
The Spectranetics Corporation develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system. The Company’s products are used to cross, prepare and treat arterial blockages in the heart and legs and to manage pacemaker and defibrillator cardiac leads.
Receive News & Ratings for Spectranetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectranetics and related companies with MarketBeat.com's FREE daily email newsletter.